Dissecting the molecular mechanisms of human cancer: Translating laboratory advances into clinical practice

Surgeon

Volumn 2, Issue 1, 2004, Pages 1-6

  Thompson, A M ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cancer; CGH; DNA; Functional yeast assay; p53; RNA

Indexed keywords

DNA; MESSENGER RNA; PROTEIN P53; TELOMERASE;

ARTICLE; BREAST CANCER; CANCER SURGERY; CARCINOGENESIS; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; POLYMERASE CHAIN REACTION; PROGNOSIS; SOLID TUMOR; TUMOR BIOPSY; TUMOR SUPPRESSOR GENE;

EID: 1242275089     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1479-666X(04)80131-8     Document Type: Article

References (29)

1. Hastie ND, Dempster M, Dunlop MG. Thompson AM, Green D et al. Telomere reduction in human colon cancer and with ageing. Nature 1990; 346: 866-868.
2. McIlrath J, Bouffler SD, Samper E, Cuthbert A, Wojcik A, Szumiel I, et al. Telomere length abnormalities in mammalian radiosensitive cells. Cancer Research 2001; 61: 912-915.
3. Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM. Expression of the hypermethylated in cancer gene (HIC-1) is associated with good outcome in human breast cancer. British Journal of Cancer 2001; 85: 1878-1892.
4. Djojosubroto MW, Choi YS, Lee HW, Rudolph KL Telomeres and telomerase in aging, regeneration and cancer. Mol Cells 2003; 15: 164-175.
5. Masutomi K, Hahn WC. Telomerase and tumorigenesis Cancer Lett 2003; 194: 163-172.
6. Esteller M. Relevance of DNA methylation in the management of cancer. Lancet Oncol 2003; 4: 351-358.
7. Slamon DJ, Clark GM, Wong SU, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987; 235: 117-182.
8. Hubbard AL, Reid CP, Thompson AM, Chetty U, Anderson TJ. Critical determination of the frequency of c-erb B2 amplification in breast cancer British Journal of Cancer 1994; 70: 434-439.
9. Steele RJC, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. British Journal of Surgery 1998; 85: 1460-1467.
10. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
11. Liem AA, Chamberlain MP, Wolf CR, Thompson AM. The role of signal transduction in cancer treatment and drug resistance. European Journal of Surgical Oncology 2002; 28: 679-684.
12. Lucke CD, Philpott A, Metcalfe JC, Thompson AM, Hughes-Davies L, Kemp PR, et al. Inhibiting mutations in the transforming growth factor-B type 2 receptor in recurrent human breast cancer. Cancer Research 2001; 61: 482-485.
13. Stocks SC, Pratt N, Sales M, Johnston DA, Thompson AM et al. Chromosomal imbalances in gastric and oesophageal adenocarcinoma: specific CGH detected abnormalities segregate with junctional adenocarcinomas. Genes, Chromosomes and Cancer 2001; 32: 50-58.
14. Thompson AM. Oesophageal and Stomach cancers. In Scenario Planning for Cancer in Scotland, Chapter 2, Scottish Executive, Edinburgh 2001.
15. Hislop RG, Stocks SC, Steel CM, Sales M, Pratt, N, Goudie D et al. Karyotypic aberrations of chromosomes 16 and 17 in breast cancer are associated with survival. British Journal of Surgery 2002; 89: 1581-1586.
16. Hupp TR, Lane DP, Ball KL Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J 2000; 352: 1-17.
17. Ziyaie D, Hupp TR, Thompson AM. p53 and breast cancer. The Breast 2000; 9: 239-246.
18. Aas T, Borresen Al, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, et al. Specific p53 mutation are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996; 2: 811-814.
19. Bertheau P, Plassa F, Espie M, Turpin, E, de Roquancourt A, Marty M, et al. Effect of mutated TP53 on respone of advanced breast cancer to high dose chemotherapy. Lancet 2002; 360: 852-854.
20. Coles C. Thompson AM, Elder PA, Cohen BB, Mackenzie IM, Cranston G, et al. At least two genes on chromosome 17 are implicated in human breast carcinogenesis. Lancet 1990; 336: 761-763.
21. Thompson AM, Anderson TJ, Condie A, Prosser J, Chetty U, Carter DC, p53 allele losses, mutations and expression in breast cancer and their relationship to clinico pathological parameters. International Journal of Cancer 1992; 50: 528-532.
22. Thompson AM, Crichton DN, Elton RA, Clay MF, Chetty U, Steel CM. Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. British Journal of Cancer 1998; 77: 797-800.
23. Phelan C, Borg A, Cuny M, Crichton DN, Baldersson T, Andersen TI, et al. Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 target sub-regions associated with family history and clinical parameters. Cancer Research 1998; 58: 1004-1012.
24. Flaman JM, Robert V, Lenglet S, Moreau V, Iggo R, Frebourg T. Identification of human p53 mutations with differential effects on th bax and p21 promotors using functional assays in yeast. Oncogene 1998; 16: 1369-1372.
25. Yagui-Beltran A, Hupp TR, Thompson AM. The yeast functional assay for p53 mutation: comparison with the HOT technique and clinical/pathological parameters. British Journal of Cancer 2001; 85: Suppl 1, 79.
26. Oglesby SD, Warbrick E, Johnston D, Dillon JF, Munro AJ, Hupp TR, et al. P53 mutations in oesophageal adenocarcinoma are common and are associated with disease response. Gut 2002; 50: Suppl 11, A92.
27. Van t'Veer LJ, Hongyue D, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
28. Ramaswamy S, Ross KN, Lander ES, Golub TR A molecular signature of metastasis in primary solid tumors. Nature Genetics 2003; 33: 49-54.
29. Anderson ARA, Chaplain MAJ, Newman EL, Steele RJC, Thompson AM. Mathematical modelling of tumour invasion and metastasis. J. Theoret Med 2000; 2: 129-154.